Last reviewed · How we verify
unfixed Latanoprost and Timolol
unfixed Latanoprost and Timolol is a Prostaglandin analogue and beta-adrenergic receptor blocker Small molecule drug developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. It is currently in Phase 3 development for Glaucoma, Ocular hypertension.
Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production.
Latanoprost is a prostaglandin analogue that reduces intraocular pressure by increasing uveoscleral outflow, while Timolol is a beta-adrenergic receptor blocker that reduces intraocular pressure by decreasing aqueous humor production. Used for Glaucoma, Ocular hypertension.
At a glance
| Generic name | unfixed Latanoprost and Timolol |
|---|---|
| Sponsor | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. |
| Drug class | Prostaglandin analogue and beta-adrenergic receptor blocker |
| Target | Beta-adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Latanoprost works by mimicking the action of a natural prostaglandin in the eye, leading to increased outflow of fluid and decreased intraocular pressure. Timolol, on the other hand, blocks the action of beta-adrenergic receptors in the eye, reducing the production of aqueous humor and subsequently lowering intraocular pressure.
Approved indications
- Glaucoma
- Ocular hypertension
Common side effects
- Blepharitis
- Eyelid skin darkening
- Itching
- Redness of the eyes
- Dry mouth
- Headache
- Dizziness
- Fatigue
Key clinical trials
- Xalacom And Combination Of Unfixed Latanoprost And Timolol In Subjects With Open-Angle Glaucoma Or Ocular Hypertension (PHASE3)
- Adherence With Fixed Versus Unfixed Glaucoma Therapy
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- unfixed Latanoprost and Timolol CI brief — competitive landscape report
- unfixed Latanoprost and Timolol updates RSS · CI watch RSS
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. portfolio CI
Frequently asked questions about unfixed Latanoprost and Timolol
What is unfixed Latanoprost and Timolol?
How does unfixed Latanoprost and Timolol work?
What is unfixed Latanoprost and Timolol used for?
Who makes unfixed Latanoprost and Timolol?
What drug class is unfixed Latanoprost and Timolol in?
What development phase is unfixed Latanoprost and Timolol in?
What are the side effects of unfixed Latanoprost and Timolol?
What does unfixed Latanoprost and Timolol target?
Related
- Drug class: All Prostaglandin analogue and beta-adrenergic receptor blocker drugs
- Target: All drugs targeting Beta-adrenergic receptor
- Manufacturer: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Glaucoma
- Indication: Drugs for Ocular hypertension
- Compare: unfixed Latanoprost and Timolol vs similar drugs
- Pricing: unfixed Latanoprost and Timolol cost, discount & access